MedTrace Logo

Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus

NCT04344379 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2025-11-20

No results posted yet for this study

Summary

The Investigators propose to set up a preventive trial of infection in hospital workers at risk of coronavirus infection by comparing the rate of SARS-Cov-2 infection in a population of negative SARS-Cov-2 hospital workers receiving preventively azithromycin, hydroxychloroquine or a Placebo

Conditions

Interventions

DRUG

hydroxychloroquine

200 mg BID per day

DRUG

azithromycin

250 mg per day

DRUG

hydroxychloroquine placebo

200 mg BID per day

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jean Ma Treluyer, MD PhD · Assitance publique - Hôpitaux de Paris.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-17
Primary Completion
2020-06-18
Completion
2020-06-18

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04344379 on ClinicalTrials.gov